Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Current Assets (2019 - 2026)

Fulcrum Therapeutics (FULC) has disclosed Current Assets for 7 consecutive years, with $357.5 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 43.04% to $357.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $357.5 million through Dec 2025, up 43.04% year-over-year, with the annual reading at $357.5 million for FY2025, 43.04% up from the prior year.
  • Current Assets for Q4 2025 was $357.5 million at Fulcrum Therapeutics, up from $205.9 million in the prior quarter.
  • The five-year high for Current Assets was $357.5 million in Q4 2025, with the low at $128.5 million in Q2 2021.
  • Average Current Assets over 5 years is $233.9 million, with a median of $230.1 million recorded in 2022.
  • The sharpest move saw Current Assets soared 89.1% in 2021, then decreased 28.03% in 2024.
  • Over 5 years, Current Assets stood at $226.0 million in 2021, then fell by 8.18% to $207.5 million in 2022, then grew by 16.71% to $242.2 million in 2023, then grew by 3.19% to $249.9 million in 2024, then soared by 43.04% to $357.5 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $357.5 million, $205.9 million, and $219.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.